€28.30
2.08% day before yesterday
Xetra, Feb 14, 05:36 pm CET
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

BIOTEST AG Stock price

€28.30
+0.70 2.54% 1M
+2.60 10.12% 6M
+1.30 4.81% YTD
-0.30 1.05% 1Y
-8.70 23.51% 3Y
+7.15 33.81% 5Y
-72.70 71.98% 10Y
Xetra, Closing price Fri, Feb 14 2025
-0.60 2.08%
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

Key metrics

Market capitalization €1.12b
Enterprise Value €1.71b
P/E (TTM) P/E ratio 16.35
EV/Sales (TTM) EV/Sales 2.42
P/S ratio (TTM) P/S ratio 1.58
P/B ratio (TTM) P/B ratio 2.12
Dividend yield 0.14%
Last dividend (FY24) €0.04
Revenue growth (TTM) Revenue growth 7.86%
Revenue (TTM) Revenue €707.00m
EBIT (operating result TTM) EBIT €90.90m
Cash position €24.70m
EPS (TTM) EPS €1.73
Show more

Is BIOTEST AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

BIOTEST AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

Hold
100%

Financial data from BIOTEST AG

Sep '24
+/-
%
Net Profit 69 69
25% 25%
10%
Depreciation and Amortization - -
-
-
Stock Compensation - -
-
-
Operating Cash Flow 91 91
198% 198%
13%
Investments - -
-
-
Dividend Paid - -
-
-
Free Cash Flow - -
-
-

In millions EUR.

Don't miss a Thing! We will send you all news about BIOTEST AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BIOTEST AG Stock News

EQS
about one month ago
Die AdFIrst-Studie war eine prospektive, aktiv-kontrollierte, multizentrische Phase-III-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Fibrinogen (BT524) bei Patienten mit erworbenem Fibrinogenmangel. Patienten, die während einer geplanten Wirbelsäulen- oder Bauchoperation einen hohen...
More BIOTEST AG News

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,426
Founded 1946
Website www.biotest.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today